Receptor inhibition was more effective in gastric adenocarcinoma cells that are triple-negative for amplification or overexpression of ERBB2, FGFR2 or MET. Subsequent experiments focused on triple-negative cancer. This evidence concerns the gene ERBB2 and gastric adenocarcinoma.